MRSA Drugs Market is Expected to Grow at a CAGR over ~ 4.4 % from 2022 to 2030

Pune, India, Oct, 2022 /MRFR Press Release/- Market Research Future has a half cooked research report on the global MRSA drugs market.

Market Highlights

The MRSA Drugs Market is projected to reach USD 4130.46 Million by 2030 at 4.4% CAGR during the forecast period 2022-2030. 

Methicillin-resistant Staphylococcus aureus (MRSA) is an antibiotic resistant strains of the pathogen. MRSA infections are classified as hospital-acquired (HA-MRSA) or community-acquired (CA-MRSA). MRSA causes infections such as skin infections, bone and joint infections, bacteremia, animal infections and others.

According to bulletin of the atomic scientists, about 10 million people in the US (3.6 percent of the population) are immune-compromised. The World Health Organization estimated that about 36.7 million people had HIV/AIDS worldwide in 2016. Thus, the rising immune-compromised population is expected to propel the market growth over the review period. Additionally, growing geriatric population projected to support the growth of the market since older people are more susceptible to MRSA infections. World Health Organization estimated that during 2015-2050, the proportion of the world's population will be nearly double from 12% to 22% and, the number of people aged over 60 years likely to outnumber children younger than 5 years.

Another strong driver is growing concerns of MRSA infections and increasing government support to curb MRSA. For example, hospital readmissions reduction program established under Affordable Care Act (ACA) financially penalizes hospitals if they have higher than expected 30-day readmission rates for diseases such as pneumonia. The recommendations of the committee has resulted in hospital readmissions national priority and a direct financial incentive to reduce readmissions. The financial incentives for reducing readmissions and the rising cost of non-compliance is expected to benefit the MRSA drugs market.

High cost of novel drug therapy and low healthcare expenditure in developing regions projected to hamper the growth of the market over the review period. Moreover, patent expiry is also expected to lower the market value due to generic competition. For example, Pfizer’s Zyvox and Merck’s Cubicin, used for the treatment of MRSA have lost patents in major markets and their patent for alternative formulations and chemical forms is threatened by imminent patent expiry dates, which is expected to lower the market due to competition from generics and greater market fragmentation.

Global MRSA Drugs Market Players

Some of the key players profiled in the report are Merck KGaA, Olon, Allergan, Baxter, Theravance Biopharma, Pfizer, Mylan N.V, Novartis, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of MRSA Drugs Market Research Report

Regional Analysis

The Americas accounts for a significant market share owing to high expenditure on the health care. The fastest uptake of new drugs in the US drives the MRSA drugs market. Furthermore, concentration of the major healthcare companies in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP that also increases the sale in MRSA drugs market.

Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. Italy is expected to be the fastest growing region over the assessment period. The strong pharmaceutical industry in Germany is a primary driver behind the dominance of this country in Europe. Southern Europe has a considerable high prevalence of MRSA as compared to Scandinavian region countries such as Iceland, Norway etc. which is driving the market faster in these nations.

Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. However Asian countries such as Indonesia, Vietnam, Japan, South Korea, Philippines, and Sri Lanka have higher prevalence and are expected to contribute highly to the market growth. The growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future MRSA drugs market in the region.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.

Taste the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global MRSA drugs Market” Research Report – Forecast till 2030.

Segmentation

The global MRSA drugs market has been segmented on the basis of drug class, MRSA types, disease indications, and end user.

Based on the drug class, the market has been segmented as sulfa drugs, tetracyclines, oxazolidinones, glycopeptide antibiotics, and other.

Based on the MRSA types, the market has been segmented as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA).

Based on the disease indications, the market has been segmented as skin infections, bone and joint infections, bacteremia, animal infections, and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.